fibrosis Model - Systemic Sclerosis
Systemic Sclerosis
Systemic Sclerosis (SSc or Scleroderma) stands as a complex autoimmune disease distinguished by vasculopathy, skin and internal organ fibrosis, inflammation, and overarching immune system irregularities. At MLM Medical Labs, our exploration into the pathogenic mechanisms underlying SSc involves the strategic use of the chemotherapeutic antibiotic bleomycin. This compound is employed to induce SSc, creating a model that captures various facets of the human disease.
In our research, we implement osmotic mini-pumps containing bleomycin, offering a refined and stable approach to modeling SSc. This method not only enhances the convenience of experimentation but also ensures a more comprehensive representation of the disease’s multiple features. Beyond its specific application in SSc research, our model holds promise for contributing to therapeutic programs addressing a broader spectrum of fibrotic diseases.
By delving into the intricacies of SSc through this advanced model, MLM Medical Labs aims to advance the understanding of autoimmune diseases and foster the development of targeted therapeutic interventions with potential implications for various fibrotic conditions.
Standard Readouts:
- Body weight
- Clinical observations
- Histology including H&E (Ashcroft Score) and MT (Collagen Score)
Additional Readouts:
- Lung and/or skin tissue cellularity
- Bronchoalveolar Lavage Fluid (BALF) cellularity
- Biomarkes including TGF-β in Bronchoalveolar Lavage Fluid (BALF) and peripheral blood
- Histology inlcuding IHC expression assessment of immune of specific markers of interest
- qPCR analysis for gene expression
- Hydroxyproline analysis: lung and/or skin collagen content
Are you interested in a variation of a model or a new paradigm?
Our scientists are passionate about the development of new models! We often participate in opportunities for co-development and pilot programs to establish new models and reach new levels of understanding.